

APPENDIX A

**VERSION WITH MARKINGS TO SHOW CHANGES MADE TO U.S. PATENT
APPLICATION SERIAL NO. 09/576,724**

In the Claims:

In reference to the amendments made herein to claim 1-2 and 12, additions appear as bolded and double under-lined text, while deletions appear in brackets, as indicated below:

1. (**Amended**) An antibody[,] capable [to] **of** selectively [bind]**binding** to [the] **a** three dimensional conformation provided by the C-terminal part of the PrP^{Sc} isoform of the prion protein or a [part] **portion** thereof, while not binding to the PrP^C form.
2. (**Amended**) The antibody according to claim 1, wherein the C-terminal part comprises a region of the prion [polypeptide] **protein** ranging from about amino acid no. 190 to amino acid no. 214[,preferably from no. 202 to 214] of the prion [polypeptide] **protein**, or variants thereof, obtained by substituting or omitting or adding one or more amino acids without changing the three dimensional configuration thereof.
12. (**Twice Amended**) A pharmaceutical composition[,] comprising:
an antibody according to claim 1[,] **and**
a suitable carrier.